New target for PARP inhibitors: some new research

[Maxone73]

"A team from The Institute of Cancer Research, London found that cancer cells which have ‘lost’ DNA repair protein RNASEH2B are killed when treated with a type of drug called a PARP inhibitor, according to the findings of a study published in the Journal of Clinical Investigation."

icr.ac.uk/news-archive/more...

[Seasid]

The Institute of Cancer Research (ICR) article discusses a study indicating that the precision drug Olaparib can successfully treat a broader range of men with advanced prostate cancer than previously thought. The study found that Olaparib is effective for patients whose tumors have genetic mutations that impair DNA repair. This expands the potential use of the drug beyond BRCA1 and BRCA2 mutations to other genetic faults. The findings suggest a significant advancement in personalized medicine for prostate cancer.